Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05945342
Other study ID # IIT2023510
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 31, 2023
Est. completion date June 30, 2025

Study information

Verified date March 2024
Source First Affiliated Hospital of Zhejiang University
Contact Huang, Manli, M.D
Phone 13957162975
Email huangmanli@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In order to realize the early identification, risk warning and comprehensive intervention of adolescent depression, this project carried out research on the diagnosis platform of adolescent depression, the construction of suicide risk warning and evaluation system, the development of interpersonal psychotherapy technology (IPT-A), and the rapid intervention technology of robotic navigation repetitive transcranial magnetic stimulation (rTMS). Through the extraction of psychological, peripheral and central biological characteristics of adolescent depression and the establishment of a diagnostic platform, combined with artificial neural network to achieve efficient and accurate identification of high risk of suicide population. Antidepressant drugs combined with psychotherapy and antidepressant drugs combined with rTMS physical therapy were used to improve the clinical effective rate and recovery rate. Finally, a comprehensive prevention and control technology suitable for hospitals, schools and families to participate in.


Description:

1. The interaction of symptoms, psychological indicators (including environmental risk factors and neuropsychology), peripheral biology (peripheral neuroimmunity, neurotrophic factors and neuroendocrine related indicators), central biological indicators (neuroimaging, near-infrared functional brain imaging) and brain-derived exosome detection in peripheral blood was constructed based on artificial intelligence technology The network of clinical diagnosis platform, and according to the high and low suicide risk classification of deep learning, the establishment of adolescent depression early identification and suicide risk warning system. 2. To develop a simplified interpersonal psychotherapy technique (IPT-A) for adolescent depression. 3. Research and development of rTMS neuroregulation technology for precise positioning of robot navigation in adolescent depression. 4. Construct comprehensive intervention models and efficacy prediction models for adolescent depression, such as drug combined with psychology and drug combined with physical therapy, and promote and demonstrate the application.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 30, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 18 Years
Eligibility Inclusion Criteria: - Sign a written informed consent to participate in the trial and receive treatment; - Meet the diagnostic criteria of depression in DSM-5, and have no psychotic characteristics; - Child Depression Rating Scale-Revised (CRs-R)=40 points; - 24 Hamilton Depression Scale (HAMD-24) scores =20; - First or recurrent depressive episode, not received antidepressant drugs and systematic psychotherapy in recent 2 months; - The Han nationality, right hand Exclusion Criteria: - Have other mental disorders, or have a history of other mental disorders, such as attention deficit movement disorder, autism, and developmental retardation; - Patients with current infections, trauma, autoimmune diseases, other unstable medical conditions, or who are receiving hormone therapy; - Patients with a history of craniocerebral injury and coma; - A family history of bipolar disorder, seizures, or epilepsy; - Those who had substance abuse or dependence within the first three months of enrollment; - Patients with contraindications for MRI examination such as metal foreign body in the skull or abnormal brain structure found in MRI examination.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Escitalopram
The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression
Other:
Interpersonal Psychotherapy for Adolescent
Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.
Escitalopram combined with psychotherapy
The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication
Escitalopram combined with rTMS
The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication
Drug:
Escitalopram combined with sham rTMS
The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication

Locations

Country Name City State
China The First Affiliated Hospital of Zhejiang University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital of Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Score of Child Depression Rating Scale-Revised For clinical depression symptom assessment Baseline, 2-week, 4-week, 8-week
Primary Score of Beck Scale for Suicide Ideation For the quantitative assessment of suicidal ideation Baseline, 2-week, 4-week, 8-week
Primary Score of Iowa Gambling Task The simulation of the real decision situation is a kind of decision making task in the fuzzy situation accompanied by corresponding rewards and punishments Baseline, 2-week, 8-week
Primary Score of THINC-it test The test includes Spotter, Symbol check, Codebreaker, Trails, and the 5-item Depression Cognitive Deficit Questionnaire (PDQ-5-D). It is used to assess working memory, executive function and attention Baseline, 2-week, 8-week
Primary Hypocretin Hypocretin is a neurotransmitter that regulates wakefulness and appetite Baseline, 2-week, 8-week
Primary Endocannabinoid Endocannabinoid play an important role in regulating many functions in the body, including the inflammatory system, immune function, sleep, appetite, digestion, pain receptors, hormones, reproductive function and memory Baseline, 2-week, 8-week
Primary Neuroimmune-related factors Such as IL-lß?IL-6?TNF-a Baseline, 2-week, 8-week
Primary Neurotrophic pathway related factors Such as BDNF?VGF?TrkB?tPA Baseline, 2-week, 8-week
Primary Near infrared functional imaging of the brain Near infrared functional brain imaging can reflect the activation degree of brain function and functional connectivity of brain by detecting the concentration changes of oxygenated hemoglobin and deoxygenated hemoglobin in the target brain area. Baseline, 2-week, 8-week
Primary Change in working memory test scores after intervention The working memory test consists of two parts, which measure the breadth and accuracy of working memory respectively. The breadth of working memory will be tested using the operating span experiment, as the accuracy of working memory will be tested using the Memory Orientation experiment Baseline, 2-week, 8-week, 24-week
Primary Change in three component test of executive function scores after intervention The three component tests of executive function were one-backward test, anti-saccade and shifting test respectively.In the one-backward test, subjects need to memorize letters while counting numbers, scoring them according to the accuracy of the alphabetic memory order; The anti-saccade test asks subjects to react to a flash of arrows (0.5 seconds) by selecting the direction they see on a keyboard;The shifting test asked subjects to select a forward or reverse feedback key depending on where the icon appeared Baseline, 2-week, 8-week, 24-week
Primary TMS-Evoked potential The integration of transcranial magnetic stimulation (TMS) and electroencephalography (EEG) is a valuable method for directly probing excitability, connectivity and oscillatory dynamics of regions throughout the brain. Offering in depth measurement of cortical reactivity, TMS-EEG allows the evaluation of TMS-evoked components that may act as a marker for cortical excitation and inhibition. Baseline, 2-week, 8-week
Primary Magnetic Resonance Imaging Functional magnetic resonance brain imaging can reflect the functional and metabolic information of neurons before morphological changes Baseline, 2-week, 8-week
Secondary Score of 24-item Hamilton Depression Rating Scale For clinical depression symptom assessment Baseline, 2-week, 4-week, 8-week
Secondary Ottawa Self-injury Questionnaire To evaluate the situation of NSSI among adolescents Baseline, 2-week, 4-week, 8-week
Secondary Score of Childhood Trauma Questionnaire Used to assess traumatic experiences in childhood Baseline
See also
  Status Clinical Trial Phase
Completed NCT01316926 - Paxil CR Bioequivalence Study Brazil Phase 1
Recruiting NCT06187454 - Transcranial Direct Current Stimulation for Depression N/A
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05768126 - Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine Phase 4
Completed NCT03219879 - Telephone-administered Relapse Prevention for Depression N/A
Recruiting NCT06038721 - Unified Protocol: Community Connections N/A
Completed NCT03043560 - Study to Treat Major Depressive Disorder With a New Medication Phase 2
Completed NCT04091139 - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong Phase 2/Phase 3
Completed NCT00069459 - Seasonal Affective Depression (SAD) Study Phase 1
Recruiting NCT05503966 - Combining Antidepressants and Attention Bias Modification in Depression N/A
Recruiting NCT03001245 - Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents N/A
Completed NCT02939560 - TMS for Adults With Autism and Depression N/A
Completed NCT02542891 - European Comparative Effectiveness Research on Internet-based Depression Treatment N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Withdrawn NCT02238730 - Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy N/A
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Completed NCT01597661 - Bupropion & Cardio Birth Defect (Slone) N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01093053 - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations N/A